Klin Farmakol Farm. 2014;28(3):108-111

Developing novel drugs to treat osteoporosis

Jan Štěpán
Revmatologický ústav a 1. lékařská fakulta UK, Praha

This is a report of recent progresses in the search for new osteoporosis therapies. The aim of treatment in patients at high risk for fractures

is to reduce the risk of a first or a subsequent fracture. Vertebral and nonvertebral fracture prevention (including the hip) using currently

available bisphosphonates, denosumab, and teriparatide is effective with a reasonable safety profile in severe osteoporosis. Initiation

of and adherence to fracture prevention drugs are still low. New potential developments of promising new drugs with new mechanisms

of action include the antiresorptive odanacatib, a selective inhibitor of cathepsin K, and osteoanabolic drugs, particularly monoclonal

antibodies against sclerostin.

Keywords: bisphosphonates, blosozumab, denosumab, fracture, odanacatib, romosozumab, sclerostin, teriparatide

Published: November 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štěpán J. Developing novel drugs to treat osteoporosis. Klin Farmakol Farm. 2014;28(3):108-111.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Svedbom A, Hernlund E, Iverg?rd M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013; 8(137): 35-42. Go to original source... Go to PubMed...
    2. Curtis JR, Cai Q, Wade SW, et al. Osteoporosis medication adherence: physician perceptions vs. patients' utilization. Bone 2013; 55(1): 1-6. Go to original source... Go to PubMed...
    3. Freemantle N, Cooper C, Diez-Perez A, et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2013; 24(1): 209-217. Go to original source... Go to PubMed...
    4. Shane E, Ebeling PR, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res 2014; 29(1): 1-23. Go to original source... Go to PubMed...
    5. Patntirapong S, Singhatanadgit W, Arphavasin S. Alendronate-induced atypical bone fracture: evidence that the drug inhibits osteogenesis. J Clin Pharm Ther 2014: 39(4): 349-353. Go to original source... Go to PubMed...
    6. McClung MR, Lewiecki EM, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2013; 24(1): 227-235. Go to original source... Go to PubMed...
    7. Štěpán J. Stroncium ranelát nemá při léčení osteoporózy osteoanabolické (duální) účinky. Čes Revmatol 2014; 22(1): 18-24.
    8. Ma YL, Zeng QQ, Chiang AY, et al. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone 2014; 59: 139-147. Go to original source... Go to PubMed...
    9. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 2009; 86(2): 175-182. Go to original source... Go to PubMed...
    10. Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 2013; 98(2): 571-580. Go to original source... Go to PubMed...
    11. Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011; 26(2): 242-251. Go to original source... Go to PubMed...
    12. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study. J Bone Miner Res 2012; 27(11): 2251-2258. Go to original source... Go to PubMed...
    13. Cheung A, Majumdar S, Brixen K, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: Improvements in bone geometry, microarchitecture and estimated bone strength. J Bone Miner Res 2014: 29(8): 1786-1794. Go to original source... Go to PubMed...
    14. Štěpán J. Stimulátory kostní novotvorby ve světle nových poznatků. Remedia 2009; 19(4): 267-271.
    15. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010; 95(1): 151-158. Go to original source... Go to PubMed...
    16. Horwitz MJ, Augustine M, Kahn L, et al. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. J Bone Miner Res 2013; 28(11): 2266-2276. Go to original source... Go to PubMed...
    17. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127(3): 469-480. Go to original source... Go to PubMed...
    18. van Lierop AH, Hamdy NA, van Egmond ME, et al. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res 2013; 28(4): 848-854. Go to original source... Go to PubMed...
    19. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370(5): 412-420. Go to original source... Go to PubMed...
    20. Ominsky MS, Niu QT, Li C, et al. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res 2014; 29(6): 1424-1430. Go to original source... Go to PubMed...
    21. Ross RD, Edwards LH, Acerbo AS, et al. Bone matrix quality after sclerostin antibody treatment. J Bone Miner Res 2014; 29(7): 1597-1607. Go to original source... Go to PubMed...
    22. Brack AS, Conboy MJ, Roy S, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science 2007; 317(5839): 807-810. Go to original source... Go to PubMed...
    23. Kansara M, Tsang M, Kodjabachian L, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009; 119(4): 837-851. Go to original source... Go to PubMed...
    24. Teletchea S, Stresing V, Hervouet S, et al. Novel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation. J Bone Miner Res 2014; 29(6): 1466-1477. Go to original source... Go to PubMed...
    25. Bonnet N, Conway SJ, Ferrari SL. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci U S A 2012; 109(37): 15048-15053. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.